Storia in 6 fonti

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.

Raccontata da

domenica 26 ottobre 2025·cnbc.com
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
domenica 26 ottobre 2025·ft.com
Novartis to buy Avidity Biosciences for $12bn
Deal for specialist in rare diseases is biggest acquisition under chief executive Vas Narasimhan

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Novartis to buy Avidity Biosciences for $12bn

Novartis comprerà Avidity Biosciences per 12 miliardi di dollari

Novartis compra Avidity Biosciences per 12 miliardi di dollari - Notizie - Ansa.it

Novartis compra Avidity Biosciences per 12 miliardi di dollari

Novartis kauft Avidity für zwölf Milliarden Dollar

Novartis CEO: We're never done with M&A